Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cutting Cost in Medicare: How About Considering Cost First?

This article was originally published in RPM Report

Executive Summary

A modest proposal for the austerity era: let the federal government factor cost into coverage decisions for Medicare Part B. For biopharma companies, that sounds like a terrible idea—but, in the long term, the alternatives just might be much worse.

You may also be interested in...

Avastin and FDA/CMS Coordination: Genentech's Safe Strategy to Save Medicare Coverage

FDA’s June Avastin hearing featured a number of points of clear disconnect between the sponsor, the agency, and other stakeholders debating the role of the therapy for metastatic breast cancer. Perhaps the biggest: the most important issue may depend on a completely different agency, CMS.

A Bad Day for Lucentis

On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.

Dendreon vs. CMS: "Full Coverage" or the CED Solution?

A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts